Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer research hub

A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administrationin Participants with Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer

This study looks at treating HER2-positive breast cancer. It compares giving a special medicine called Phesgo at home versus in the hospital to see which patients prefer. Researchers also check how well the treatment works and any side effects.